BioNTech all set to supply new Covid jab 'very soon' to neutralise Omicron

German biotechnology company BioNTech is planning to start distributing, from early next month, a new Covid-19 vaccine that has been developed to neutralise two Omicron variants

vaccine
IANS Berlin
2 min read Last Updated : Aug 25 2022 | 5:28 PM IST

German biotechnology company BioNTech is planning to start distributing, from early next month, a new Covid-19 vaccine that has been developed to neutralise two Omicron variants.

"We will be able to deliver very soon, hopefully at the beginning of September," BioNTech chief executive Ugur Sahin said, DPA news agency reported, citing Der Spiegel.

The European Medicines Agency (EMA) recently announced that it would decide on applications from BioNTech-Pfizer and Moderna regarding their vaccines adapted for the BA.1 variant of the virus. However, this variant is of declining importance in Europe.

The new vaccine is, however, still expected to be more effective in neutralising the variants currently in circulation, the report said.

The EMA is currently testing a vaccine adapted by BioNTech and its US partner Pfizer for the BA.4 and BA.5 variants currently dominant in Europe.

BioNTech was currently submitting the last documents to the EMA, Sahin told Der Spiegel. "Then things can precede quickly here as well," he said.

Meanwhile, a recent report said that the Pfizer-BioNTech Covid-19 vaccine was 73 per cent effective in protecting children ages 6 months through 4 years during the time when the Omicron strain was highly prevalent.

The vaccine was granted Emergency Use Authorisation by the US Food and Drug Administration for this age group on June 17.

--IANS

vc/vd

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

Subscribe to Business Standard digital and get complimentary access to The New York Times

Quarterly Starter

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

Save 46%

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Access to Exclusive Premium Stories Online

  • Over 30 behind the paywall stories daily, handpicked by our editors for subscribers

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :OmicronCoronavirus Vaccine

First Published: Aug 25 2022 | 5:28 PM IST

Next Story